Exclusive Summary

• - Fully off-patent globally with no meaningful IP barriers, enabling fast market entry via distribution
• - Large, steady demand driven by tens of millions of eye surgeries and over 100 million conjunctivitis episodes annually
• - Fluoroquinolones are mainstream for bacterial conjunctivitis/keratitis and peri‑operative prophylaxis; 0.5% levofloxacin is a widely used strength
• - API complies with JP/EP/USP/BP/Ph.Int., easing multi‑region filings and unified quality control
• - Strong cost advantage versus originators and 4th‑gen fluoroquinolones, competitive in tenders and retail